MDedge Neurology

MDEdge Neurology provides updates on the latest advancements and discoveries in the fields of neurology and neuroscience, keeping its audience informed about clinical progress that affects patient care. The platform offers timely notifications on new research related to conditions such as dementia, movement disorders, epilepsy, headaches, strokes, multiple sclerosis, and other neurological issues. This information is gathered by experienced reporters who participate in numerous medical conferences each year, review scholarly articles, follow discussions from the Food and Drug Administration's advisory panels, and engage with leading experts in patient care. Additionally, the health policy team at MDedge Neurology shares essential insights with neurologists regarding regulatory, legislative, and economic changes that could influence medical practice.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#80128

United States

#24476

Health/Health

#584

Traffic sources

Monthly visitors

Articles

Elemental Diet Eases Symptoms in Microbiome Gastro Disorders

1 week ago | mdedge.com | Heidi Splete

FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGYShort-term adherence to a palatable elemental diet (PED) significantly improved symptoms and the gut microbiota in adults with microbiome-driven gastrointestinal disorders, according to a new study.
What Hematologists Should Know About Cutaneous Porphyria and Hemochromatosis

1 week ago | mdedge.com | Randy Dotinga

One patient, a 39-year-old woman, went to a dermatologist seeking care for fluid-filled blisters over the backs of her hands and arms. Another patient, a 56-year-old man, sought care from his general practitioner owing to fatigue. Their presentations were quite different, but the two patients shared one thing in common: iron overload. Both ended up in the care of hematologists who diagnosed their conditions as porphyria cutanea tarda (PCT) and hemochromatosis, respectively.
FDA Approves Avastin Biosimilar Agent, Jobevne

1 week ago | mdedge.com | Sharon Worcester

The United States Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer types. Approval was based on “a comprehensive package of comparative pharmacokinetic, safety, efficacy, nonclinical, structural, analytical and functional data, which confirmed the Jobevne is highly similar to Avastin,” according to a Biocon Biologics Ltd press release.
FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC

1 week ago | mdedge.com | Sharon Worcester

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC).
Radiation Oncology Reimbursement: New Bill Rocks the Boat

1 week ago | mdedge.com | Sharon Worcester

A renewed effort to modernize and stabilize Medicare reimbursement for radiation therapy services is underway. In mid-March, members of Congress reintroduced bipartisan federal legislation that would shift Medicare reimbursement for radiation oncology services from quantity-based payments to episode-based payments and help stabilize the declining rates of reimbursement in the field.
How Doctors Use Travel to Heal Themselves

2 weeks ago | mdedge.com | Dina Cheney

Whatever’s ailing you, a vacation might just be the cure. Yes, getting away can improve your health, according to research published in in 2023. It might help combat symptoms of aging, suggested a 2024 study in Journal of Travel Research. But it could also have even more powerful psychological and physical benefits, transforming your life before you pack a bag and long after you return home. This news organization spoke with two healthcare professionals who believe in the healing power of travel.
Assay Shows Promise for Early-Stage Melanoma Risk Assessment Beyond SNLB

2 weeks ago | mdedge.com | Sharon Worcester

FROM WCM-EADO 2025A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do not undergo sentinel lymph node biopsy (SNLB).
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

3 weeks ago | mdedge.com | Sharon Worcester

Consent Legitimate InterestAlways ActiveThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
The Physician Associate Advantage: A Vital Solution for Better Patient Care

3 weeks ago | mdedge.com | Kayt Sukel

Late last year, the Health Resources and Services Administration projected a shortage of nearly 190,000 physicians across specialties by 2037. They noted, however, that we could mitigate the lack of doctors in some specialties by increasing the use of physician associates (PAs), especially with new and pending legislation expanding PAs’ scope of practice.
A Better Biopsy for Prostate Cancer?

4 weeks ago | mdedge.com | Howard Wolinsky

Micro-ultrasound–guided biopsies were found for the first time to be “noninferior” to MRI-guided procedures, according to new research presented at the 2025 annual congress of the European Association of Urology. The OPTIMUM study found 4.5% more clinically significant cancers among men who underwent micro-ultrasound–guided biopsies of the prostate than in those scanned using MRI.